Spots Global Cancer Trial Database for Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Official Title: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Study ID: NCT00790400
Study Description
Brief Summary: This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Barrow Tuberous Sclerosis Center, Phoenix, Arizona, United States
Massachusetts General Hospital Massachussetts General Hospita, Boston, Massachusetts, United States
Minnesota Epilepsy Group, St. Paul, Minnesota, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
LeBonheur Childrens Medical Group SC-2, Memphis, Tennessee, United States
Novartis Investigative Site, Torono, Ontario, Canada
Novartis Investigative Site, Lyon, , France
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, München, , Germany
Novartis Investigative Site, Siena, SI, Italy
Novartis Investigative Site, Torino, TO, Italy
Novartis Investigative Site, Roma, , Italy
Novartis Investigative Site, Sapporo-city, Hokkaido, Japan
Novartis Investigative Site, Suita-city, Osaka, Japan
Novartis Investigative Site, Yamagata, , Japan
Novartis Investigative Site, Utrecht, , Netherlands
Novartis Investigative Site, Warszawa, , Poland
Novartis Investigative Site, Warszawa, , Poland
Novartis Investigative Site, Moscow, , Russian Federation
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Brighton, East Sussex, United Kingdom
Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom
Novartis Investigative Site, Cardiff, Wales, United Kingdom
Novartis Investigative Site, London, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
